Dyadic International Inc key statistics and ratios
In fiscal 2025, Dyadic International Inc had an operating margin of -232.8%, debt equal to 0.0% of equity and a current ratio of 2.68. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 10.3% | 20.7% | 13.2% | 11.0% | 19.1% | 27.5% | 31.8% | 65.8% | 24.9% | 16.2% |
| Operating margin | −939.7% | −586.1% | −552.2% | −625.9% | −612.7% | −346.9% | −283.9% | −168.8% | −232.8% | −195.1% |
| Net margin | −281.6% | −439.4% | −494.2% | −582.1% | −543.7% | −332.2% | −234.4% | −166.2% | −238.3% | −200.5% |
| Return on equity | −4.3% | −12.3% | −21.2% | −29.0% | −55.8% | −66.1% | −80.1% | −139.2% | — | — |
| Return on assets | −4.2% | −12.1% | −20.6% | −27.6% | −50.9% | −55.6% | −62.0% | −64.0% | −74.1% | −92.5% |
| Asset turnover | 0.01 | 0.03 | 0.04 | 0.05 | 0.09 | 0.17 | 0.26 | 0.39 | 0.31 | 0.46 |
| Current ratio | 64.53 | 50.31 | 22.44 | 18.32 | 8.22 | 5.48 | 3.58 | 4.01 | 2.68 | 1.65 |
| Debt to equity | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| R&D as % of revenue | 232.8% | 162.2% | 183.7% | 241.5% | 349.1% | 153.6% | 113.7% | 58.5% | 69.7% | 48.4% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 79.8% | 56.8% | 24.4% | 36.5% | 12.1% | 32.0% | 28.7% | −2.4% |
| Operating margin | −10.4% | −187.2% | −508.8% | −178.9% | −165.3% | −271.6% | −171.3% | −213.7% |
| Net margin | −10.4% | −189.7% | −515.2% | −185.6% | −169.7% | −277.1% | −175.9% | −221.0% |
| Current ratio | 5.15 | 4.01 | 3.98 | 2.02 | 2.85 | 2.68 | 2.42 | 1.65 |
| R&D as % of revenue | 23.5% | 66.8% | 125.8% | 65.1% | 49.1% | 81.1% | 42.9% | 34.6% |
Financial health
- Short-term assets cover short-term liabilities $6m of assets due within a year against $4m of liabilities due within a year.
- Short-term assets cover long-term liabilities $6m short-term assets against $5m of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Moat
Weak moat
How hard Dyadic International's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -65.9% of total assets over 8 years.
- Pricing power 0 / 20
Gross margin has been a median 18.7%, moving by 18.5 percentage points (standard deviation) across 8 years.
- Durability 10 / 20
Operating margin has been a median -480.0%; its worst year was -720.3%.
- Discipline 0 / 20
The diluted share count rose 33.4% over five years; stock-based pay has been a median 61.9% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).
Compare with peers
- DBV Technologies S.a. statistics
- Aligos Therapeutics, Inc. statistics
- Camp4 Therapeutics Corp statistics
- Curis Inc statistics
- Xenetic Biosciences, Inc. statistics
Head to head: DBVT vs DYAIALGS vs DYAICAMP vs DYAIDYAI vs XBIO
More: Biotechnology stocks compared, Health Care sector, rankings of US companies